Latest Conference Articles

June 3rd 2013, 7:40am

ASCO Annual Meeting

Bevacizumab combined with either of two chemotherapy backbones improved overall survival by 3.7 months versus chemotherapy alone in patients with advanced cervical cancer.

June 3rd 2013, 7:26am

ASCO Annual Meeting

Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

June 3rd 2013, 6:59am

ASCO Annual Meeting

Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.

June 3rd 2013, 5:34am

ASCO Annual Meeting

Interim findings from a randomized, global, phase III study indicate that the multi-targeted drug sorafenib nearly doubled PFS for patients with differentiated thyroid cancer resistant to radioactive iodine therapy.

June 2nd 2013, 1:14pm

ASCO Annual Meeting

Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.

June 2nd 2013, 12:28pm

ASCO Annual Meeting

Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.

June 2nd 2013, 10:33am

ASCO Annual Meeting

Marcia Brose, MD, PhD, from the Abramson Cancer Center at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

June 2nd 2013, 7:50am

ASCO Annual Meeting

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

June 2nd 2013, 7:38am

ASCO Annual Meeting

Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.

June 2nd 2013, 7:31am

ASCO Annual Meeting

Patients with human papilloma virus–positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.

June 2nd 2013, 7:03am

ASCO Annual Meeting

An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.

June 2nd 2013, 6:15am

ASCO Annual Meeting

Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.

June 2nd 2013, 5:35am

ASCO Annual Meeting

Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.

June 2nd 2013, 5:26am

ASCO Annual Meeting

Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.

June 2nd 2013, 5:23am

ASCO Annual Meeting

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

June 1st 2013, 11:41am

ASCO Annual Meeting

Gypsyamber D‘Souza, PhD, MPH, MS, from Johns Hopkins University, discusses the prevalence of oral HPV infections in the spouses of patients with HPV-positive oropharyngeal cancer.

June 1st 2013, 10:03am

ASCO Annual Meeting

Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.

June 1st 2013, 8:57am

ASCO Annual Meeting

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.

June 1st 2013, 6:15am

ASCO Annual Meeting

New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.

June 1st 2013, 5:22am

ASCO Annual Meeting

Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.